Trial Profile
Efficacy and Safety of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Advanced Stage HCC
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Camrelizumab (Primary) ; Catequentinib (Primary) ; Donafenib (Primary) ; Durvalumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Penpulimab (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary) ; Sorafenib (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms CHANCE2201
- 28 Dec 2022 Planned primary completion date changed from 31 Aug 2022 to 30 Aug 2022.
- 28 Dec 2022 Status changed from not yet recruiting to recruiting.
- 21 Apr 2022 New trial record